<SEC-DOCUMENT>0001193125-24-178664.txt : 20240715
<SEC-HEADER>0001193125-24-178664.hdr.sgml : 20240715
<ACCEPTANCE-DATETIME>20240712190156
ACCESSION NUMBER:		0001193125-24-178664
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20240712
FILED AS OF DATE:		20240715
DATE AS OF CHANGE:		20240712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241115492

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d729734d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as July 12, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d729734dex991.htm">Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression</A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: July 12, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d729734dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g729734dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g729734dsp4a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with
Negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> Expression </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efti in combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab)
achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS &lt;1 </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">High complete response rate of 9.7% with three patients showing a disappearance of cancer lesions post treatment
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Durability of responses tracks well and over 50% of patients received treatment for at least six months
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Combination continues to have a favourable safety profile with no new safety signals observed
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Based on encouraging results and high unmet medical need, the path forward will be discussed with regulatory
agencies </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Company to host webcast today at 9am AEST (7pm ET, 11 July), details below </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; July</B><B></B><B>&nbsp;12, 2024 &#150;</B> Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces positive results from Cohort B of the <FONT
STYLE="white-space:nowrap">TACTI-003</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(KEYNOTE-PNC-34)</FONT></FONT> Phase IIb trial evaluating eftilagimod alfa (efti) in combination with MSD&#146;s (Merck&nbsp;&amp; Co.,
Inc., Rahway, NJ, USA) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first-line treatment of recurrent or
metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. The updated efficacy and safety data was presented by Dr.&nbsp;Robert Metcalf during an oral presentation at
the ESMO Virtual Plenary session at <FONT STYLE="white-space:nowrap">18:30-19:30</FONT> CEST on 11&nbsp;July 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The investigational immuno-oncology (IO) combination utilising efti and KEYTRUDA achieved an objective response rate (ORR) of 35.5% (11 of 31 evaluable
patients) and a disease control rate (DCR) of 58.1%, according to RECIST 1.1, in 1L HNSCC patients whose tumours do not express <FONT STYLE="white-space:nowrap">PD-L1</FONT> (Combined Positive Score [CPS] &lt;1). These results are among the highest
recorded for a chemotherapy-free approach in negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> patients and compare favourably to a historical control of 5.4% ORR and 32.4% DCR from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the IO combination
attained a high complete response rate of 9.7% (3 of 31 patients), which compares favourably to a historical control of 0% from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy in 1L HNSCC
patients with a CPS &lt;1.<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> Notably, one patient with early progressive disease according to RECIST 1.1 has evolved into a confirmed partial responder who remains on therapy after 14 months,
resulting in a 38.7% ORR for the <FONT STYLE="white-space:nowrap">IO-combination,</FONT> according to iRECIST. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g729734dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g729734dsp4a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Robert Metcalf, MD, PhD, The Christie NHS Foundation Trust, Manchester, U.K., stated,</B> &#147;The high response rate
from this novel immunotherapy combination is well above other treatment approaches without chemotherapy. It matches historical response rates from chemotherapy-based treatments but without the associated toxicities. This is really significant for
patients with head and neck squamous cell carcinomas who have a CPS less than one and for whom chemotherapy is the current first line treatment. Achieving complete responses in this group bodes well for this immunotherapy combination&#146;s future
potential, especially given the positive trend in response durability. The clinically meaningful response rate and high unmet medical need warrant further investigation of eftilagimod plus pembrolizumab in this patient population.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Durability of Responses and Favourable Safety </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Durability
of responses is tracking well as has been seen in other clinical trials when efti is combined with KEYTRUDA. Over 50% of patients in Cohort B received treatment for at least six months with three additional patients nearing this threshold at the
time of data cut off (11 March 2024). The combination also continues to have a favourable safety profile with no new safety signals observed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This new
data adds to the body of evidence that efti&#146;s novel activation of antigen-presenting cells provides a strong boost to the immune system, enhancing the potential of immune checkpoint inhibitors such as KEYTRUDA. Importantly, as the only MHC
Class&nbsp;II agonist in clinical development today, efti is generating a broad anti-cancer immune response in a unique and safe manner across all levels of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, especially in patients with
negative expression (CPS &lt;1). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Steps </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based
on the encouraging efficacy and high unmet medical need, Immutep will discuss the path forward with regulatory agencies. Efti has received FDA Fast Track designation in 1L HNSCC regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression.
The prevalence for CPS &lt;1, CPS <FONT STYLE="white-space:nowrap">1-19,</FONT> and CPS <U>&gt;</U>20 <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression levels are approximately 20%, 30%, and 50% of the HNSCC patient population, respectively.<SUP
STYLE="font-size:75%; vertical-align:top">3</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Webcast Details </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep will host a webcast to discuss the clinical data. A replay of the webcast will be available under the Events section of Immutep&#146;s website after
the event. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date/Time:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Friday, July&nbsp;12, at 9am AEST (7pm ET July 11)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Register:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Link to register for webcast</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Questions:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investors are invited to submit questions in advance via immutep@morrowsodali.com</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme
LLC, a subsidiary of Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the <FONT STYLE="white-space:nowrap">TACTI-003</FONT> Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">TACTI-003</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(KEYNOTE-PNC-34)</FONT></FONT> trial is
an ongoing Phase IIb study evaluating eftilagimod alfa (efti), Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist, in combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc.,
Rahway, NJ, USA) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first line treatment of recurrent or metastatic
head and neck squamous cell carcinoma (HNSCC). The randomized Cohort A portion of the study is evaluating efti in combination with pembrolizumab as compared to pembrolizumab monotherapy in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT>
positive (Combined Positive Score [CPS] &#8805;1) tumours, whereas Cohort B is evaluating efti in combination with pembrolizumab in patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> negative tumours. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g729734dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g729734dsp4a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint of the study is Overall Response Rate of evaluable patients according to RECIST 1.1. Secondary
endpoints include Overall Survival, Overall Response Rate according to iRECIST, Progression Free Survival, and Duration of Response. For more information about the Phase IIb trial, visit clinicaltrials.gov (NCT04811027). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alfa (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells,
CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further
boost the immune system&#146;s ability to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug
Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a
clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte
Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to
leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow
Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; c.strong@morrowsodali.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; chris.basta@immutep.com </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1,2</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Burtness, B. et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous
Cell Carcinoma in <FONT STYLE="white-space:nowrap">KEYNOTE-048:</FONT> Subgroup Analysis by Programmed Death <FONT STYLE="white-space:nowrap">Ligand-1</FONT> Combined Positive Score. <I>Journal of Clinical Oncology</I> 2022 40:21, 2321-2332. Note,
the 5.4% ORR and 32.4% DCR are calculated from the 37 evaluable patients with CPS &lt;1. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent
or metastatic squamous cell carcinoma of the head and neck <FONT STYLE="white-space:nowrap">(KEYNOTE-048):</FONT> a randomised, open-label, phase 3 study <I>The Lancet</I> Volume 394, Issue 10212, P1915-1928, Nov 2019. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g729734dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g729734dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MI,VKZG+(0/-U&UO[58KED10B.8[VXCPH4!2% PH Y\IJSEB:W-)R]I'FE?\
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M:'A?PO;6^J!&1=6OIKK5-3B1AM=;>ZU":4V@9<AO($6X$ALBC8-CUGI^'Z4
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? * "@ H * "@ H * "@ H * "@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g729734dsp4a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g729734dsp4a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M?&G_ ).__&*/K6._Y^U?Q_R#^U,^_P"@O%_=/_Y$/^%B?%__ *&7QI_Y._\
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M *"\7]T__D0_X6)\7_\ H9?&G_D[_P#&*/K6._Y^U?Q_R#^U,^_Z"\7]T_\
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MR#^U,^_Z"\7]T_\ Y$/^%B?%_P#Z&7QI_P"3O_QBCZUCO^?M7\?\@_M3/O\
MH+Q?W3_^1#_A8GQ?_P"AE\:?^3O_ ,8H^M8[_G[5_'_(/[4S[_H+Q?W3_P#D
M0_X6)\7_ /H9?&G_ ).__&*/K6._Y^U?Q_R#^U,^_P"@O%_=/_Y$/^%B?%__
M *&7QI_Y._\ QBCZUCO^?M7\?\@_M3/O^@O%_=/_ .1#_A8GQ?\ ^AE\:?\
MD[_\8H^M8[_G[5_'_(/[4S[_ *"\7]T__D0_X6)\7_\ H9?&G_D[_P#&*/K6
M._Y^U?Q_R#^U,^_Z"\7]T_\ Y$/^%B?%_P#Z&7QI_P"3O_QBCZUCO^?M7\?\
M@_M3/O\ H+Q?W3_^1#_A8GQ?_P"AE\:?^3O_ ,8H^M8[_G[5_'_(/[4S[_H+
MQ?W3_P#D0_X6)\7_ /H9?&G_ ).__&*/K6._Y^U?Q_R#^U,^_P"@O%_=/_Y$
M/^%B?%__ *&7QI_Y._\ QBCZUCO^?M7\?\@_M3/O^@O%_=/_ .1#_A8GQ?\
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M_A8GQ?\ ^AE\:?\ D[_\8H^M8[_G[5_'_(/[4S[_ *"\7]T__D0_X6)\7_\
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M_P B?9VD_P#(*TS_ +!]E_Z31U]:?L1Z7X,_Y%^#_L(:]_Z?M3H ZF@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \+TG_D%:9_V
*#[+_ -)HZ /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
